Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 1/20 | 0.57 |
| ▸ | TOP2B known ✓ | Q02880 | 1/20 | 0.57 |
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.54 |
| ▸ | WDR5 | P61964 | 1/20 | 0.95 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.70 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.70 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.70 |
| ▸ | C1S | P09871 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | F2 | P00734 | 2/20 | 0.68 |
| ▸ | F10 | P00742 | 1/20 | 0.68 |
| ▸ | F12 | P00748 | 1/20 | 0.68 |
| ▸ | F7 | P08709 | 1/20 | 0.68 |
| ▸ | F3 | P13726 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | NQO2 | P16083 | 7/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021876 | 0.98 | WDR5 (1.00) | WDR5BLMPRSS1PRSS3PRSS2 | |
| Biphenyl SCHEMBL2456187 | 0.93 | BLM (0.85) | WDR5BLMPRSS1PRSS3PRSS2 | |
| Biphenyl SCHEMBL28438673 | 0.90 | WDR5 (0.86) | WDR5BLMPRSS1PRSS3PRSS2 | |
| SCHEMBL26081559 | 0.89 | WDR5 (0.83) | WDR5BLMPRSS1PRSS3PRSS2 | |
| SCHEMBL8973288 | 0.87 | WDR5 (0.80) | WDR5BLMPRSS1PRSS3PRSS2 | |
| SCHEMBL394218 | 0.87 | WDR5 (0.80) | WDR5BLMPRSS1PRSS3PRSS2 | |
| Benzamidine SCHEMBL23235801 | 0.85 | BLM (1.00) | WDR5BLMPRSS1PRSS3PRSS2 | |
| Benzamidine SCHEMBL6861235 | 0.85 | BLM (1.00) | WDR5BLMPRSS1PRSS3PRSS2 | |
| Benzamidine SCHEMBL29191424 | 0.85 | BLM (1.00) | WDR5BLMPRSS1PRSS3PRSS2 | |
| Benzamidine SCHEMBL27303891 | 0.85 | BLM (1.00) | WDR5BLMPRSS1PRSS3PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120166906-A | Two-dimensional/three-dimensional perovskite heterojunction based on amidino cation and application of perovskite heterojunction in solar cell | 西安交通大学 | 2025-06-17 | — | — | CN | claimed |
| CN-120166906-A | Two-dimensional/three-dimensional perovskite heterojunction based on amidino cation and application of perovskite heterojunction in solar cell | 西安交通大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-117926289-A | Method for electrochemically synthesizing N-sulfoamidine derivatives under mild condition | 湘潭大学 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-115010673-B | Method for synthesizing 1,3, 5-triazine compounds under visible light-induced metal-free catalysis condition | 河南大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-115010673-A | Method for synthesizing 1,3,5-triazine compound under visible light induction and metal-free catalysis condition | 河南大学 | 2022-09-06 | — | — | CN | disclosed |
| WO-2022173265-A1 | ORGANIC LUMINESCENT COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | (주)피엔에이치테크 | 2022-08-18 | — | — | WO | disclosed |
| CN-114126866-A | Vinylidene fluoride resin multilayer film, film for automobile interior and exterior decoration, automobile part, and automobile | 电化株式会社 | 2022-03-01 | — | — | CN | disclosed |
| CN-111606865-B | Asymmetric substituted 1,3, 5-triazine compound and preparation method and application thereof | 吉林大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-108264490-B | 1,3, 5-triazine derivative and preparation method and application thereof | 湖北尚赛光电材料有限公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2003035734-A1 | NAPHTHYLTRIAZINES AS STABILIZERS FOR ORGANIC MATERIAL | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-05-01 | — | — | WO | disclosed |
| US-20030045444-A1 | Biphenyl-substituted triazines | FLETCHER IAN JOHN (CH) | 2003-03-06 | — | — | US | disclosed |
| US-6468958-B2 | LIGHT, OXYGEN AND HEAT RESISTANCE | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-10-22 | — | — | US | disclosed |
| EP-0815089-B1 | BIPHENYL-SUBSTITUTED TRIAZINES AS LIGHT STABILIZER | CIBA SC HOLDING AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| EP-1213283-A2 | Biphenyl-substituted triazines as light stabilisers | Ciba SC Holding AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| US-20010039341-A1 | Biphenyl-Substituted Triazines | FLETCHER IAN JOHN (CH) | 2001-11-08 | — | — | US | disclosed |
| US-6255483-B1 | USEFUL AS LIGHT STABILIZERS FOR TEXTILE FIBER MATERIALS AND SUNSCREENS FOR HUMAN SKIN | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-07-03 | — | — | US | disclosed |
| CN-1178527-A | Biphenyl-substituted triazines as light stabilizers | CIBA GEIGY AG (CH) | 1998-04-08 | — | — | CN | disclosed |
| EP-0815089-A1 | BIPHENYL-SUBSTITUTED TRIAZINES AS LIGHT STABILIZER | Ciba SC Holding AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028431-A1 | BIPHENYL-SUBSTITUTED TRIAZINES AS LIGHT STABILIZER | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045444-A1 | Biphenyl-substituted triazines | TYR, CYP1B1, NFE2L2 | TOP2A 86/4885TOP2B 107/4885TOP1 96/4885 |
| US-20010039341-A1 | Biphenyl-Substituted Triazines | TYR, CYP1B1, NFE2L2 | TOP2A 86/4885TOP2B 107/4885TOP1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.